L-5-Hydroxytryptophan-d4

L-5-Hydroxytryptophan-d4

• CAS Number: 1246818-91-6
• UNSPSC Description: L-5-Hydroxytryptophan-d4 (L-5-HTP-d4; Oxitriptan-d4) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[1]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[2][3][4][5][6].
• Target Antigen: Endogenous Metabolite; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Metabolic Enzyme/Protease;Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Purity: 98.71
• Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming)
• Smiles: OC([C@@H](N)CC(C1=C2[2H])=C([2H])NC1=C([2H])C([2H])=C2O)=O
• Molecular Weight: 224.25
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.|[2]ARVID CARLSSON, et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 180, page1200 (1957).|[3]Caruso I, et al. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9.|[4]Thal LJ, et al. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol. 1980 Jun;7(6):570-6.|[5]Boiardi A, et al. 5-OH-Tryptophane in migraine: clinical and neurophysiological considerations. J Neurol. 1981;225(1):41-6.|[6]Trouillas P, et al. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988 Nov;45(11):1217-22.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported